Depression Drug Market Size, Share, and Trends Analysis Report

CAGR :  Diagram

Market Size 2023 (Base Year) USD 15.84 Billion
Market Size 2032 (Forecast Year) USD 23.74 Billion
CAGR 4.6%
Forecast Period 2024 - 2032
Historical Period 2018 - 2023

Depression Drug Market Insights

A latest report by Market Research Store estimates that the Global Depression Drug Market was valued at USD 15.84 Billion in 2023 and is expected to reach USD 23.74 Billion by 2032, with a CAGR of 4.6% during the forecast period 2024-2032. The report Depression Drug Market overview, growth factors, restraints, opportunities, segmentation, key developments, competitive landscape, consumer insights, and market growth forecast in terms of value or volume. These structured details offer an all-inclusive market overview, providing valuable insights for investment decisions, business decisions, strategic planning, and competitive analysis.

Depression Drug Market Size

To Get more Insights, Request a Free Sample

Depression Drug Market: Report Scope

Report Attributes Report Details
Report Name Depression Drug Market
Market Size in 2023 USD 15.84 Billion
Market Forecast in 2032 USD 23.74 Billion
Growth Rate CAGR of 4.6%
Number of Pages 110
Key Companies Covered Forest Laboratories, AstraZeneca, GlaxoSmithKline, Abbott Laboratories, H. Lundbeck, Novartis, SK Biopharmaceuticals, Naurex Merck & Co., and Eli Lilly and Company
Segments Covered By Class, By , And By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)
Base Year 2023
Historical Year 2018 to 2023
Forecast Year 2024 to 2032
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization


The report covers forecast and analysis for the depression drug market on a global and regional level. The study provides historic data of 2014 along with a forecast from 2015 to 2020 based revenue (USD Million). The study includes drivers and restraints for the depression drug market along with the impact they have on the demand over the forecast period. Additionally, the report includes study of opportunities available in the depression drug market on a global level.

In order to give the users of this report a comprehensive view on the depression drug market, we have included a detailed competitive scenario, and product portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter’s five forces model for the depression drug market has also been included. The study encompasses a market attractiveness analysis, wherein application segments are benchmarked based on their market size, growth rate and general attractiveness.

The study provides a decisive view on the depression drug market by segmenting the market based class and region. The different classs of depression also have different symptoms, including major or clinical depressive disorder, postpartum depression, dysthymic disorder, psychotic depression and seasonal affective disorder. Depending upon class global depression drug market is segmented as anticonvulsants, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), beta-blockers, benzodiazepines, tetracyclic antidepressants (TeCAs) and monoamine oxidase inhibitors (MAOIs) among others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East and Africa with its further bifurcation into major countries including U.S. Germany, France, UK, China, Japan, India and Brazil.

The report covers detailed competitive outlook including company profiles of the key participants operating in the global market. Key players profiled in the report include Forest Laboratories, AstraZeneca, GlaxoSmithKline, Abbott Laboratories, H. Lundbeck, Novartis, SK Biopharmaceuticals, Naurex Merck & Co., and Eli Lilly and Company.

This report segments the global drug depression market as follows:

Global Depression Drug Market: Class Segment Analysis

  • Atypical Antipsychotics
  • Tricyclic Antidepressants
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin-Norepinephrine Reuptake Inhibitors
  • Tetracyclic Antidepressants
  • Monoamine Oxidase inhibitors
  • Benzodiazepines
  • Others

Global Depression Drug Market: Regional Segment Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Frequently Asked Questions

These dominant industry players use well planned strategies to occupied highest market share in this market. Some of the top players in [Keyword] business includes. [Company list]
As per [Keyword] market analysis, North America is forecasted to occupied major share in the [Keyword] market.
The statistical data of the dominant industry player of [Keyword] market can be acquired from the company profile segment described in the report. This segment come up with analysis of major player’s in the [Keyword] market, also their last five-year revenue, segmental, product offerings, key strategies adopted and geographical revenue produced.
The report come up with a segment of the [Keyword] market based on Type, Region, and Application, Also offer a determined view on the [Keyword] market.
The report offers a nitty-gritty estimation of the market by providing data on various viewpoints that incorporate, restraints, drivers, and opportunities threats. This data can help in making suitable decisions for stakeholders before investing.
The sample report for [Keyword] market can be received after the apply from the website.

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global market revenue, 2014 - 2020(USD Million)
    • 2.2. Global depression drug market: Snapshot
  • Chapter 3. Depression drug market – Global and Industry Analysis
    • 3.1. Depression drug: Market dynamics
    • 3.2. Market drivers
      • 3.2.1. Drivers of global depression drug market: Impact analysis
      • 3.2.2. Escalating prevalence of anxiety and depression disorders
      • 3.2.3. Rising efficiency and declining side effects of drugs in numerous classes
    • 3.3. Market restraints
      • 3.3.1. Restraints of global depression drug market: Impact analysis
      • 3.3.2. Expiry of main antidepressants
      • 3.3.3. Weak pipeline of new drugs
    • 3.4. Opportunities
      • 3.4.1. Small market penetration in developing countries
    • 3.5. Porter’s five forces analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis by class segment
      • 3.6.2. Market attractiveness analysis by regional segment
  • Chapter 4. Global Depression drug market - Competitive Landscape
    • 4.1. Company market share, 2014
    • 4.2. Price trend analysis
  • Chapter 5. Global Depression drug market : Class Overview
    • 5.1. Global depression drug market share, by class, 2014 and 2020
    • 5.2. Global depression drug market for atypical antipsychotics, 2014 - 2020 (USD Million)
    • 5.3. Global depression drug market for tricyclic antidepressants, 2014 - 2020 (USD Million)
    • 5.4. Global depression drug market for selective serotonin reuptake inhibitors, 2014 - 2020 (USD Million)
    • 5.5. Global depression drug market for tetracyclic antidepressants, 2014 – 2020 (USD Million)
    • 5.6. Global depression drug market for monoamine oxidase inhibitors, 2014 – 2020 (USD Million)
    • 5.7. Global depression drug market for benzodiazepines, 2014 – 2020 (USD Million)
    • 5.8. Global depression drug market for others, 2014 – 2020 (USD Million)
  • Chapter 6. Global Depression drug market – Regional Segment Analysis
    • 6.1. Global depression drug market : Regional overview
      • 6.1.1. Global depression drug market revenue share, by region, 2014 and 2020
    • 6.2. North America
      • 6.2.1. North America depression drug market revenue, by class, 2014 – 2020 (USD Million)
      • 6.2.2. U.S.
        • 6.2.2.1. U.S. depression drug market revenue, by class, 2014 – 2020 (USD Million)
    • 6.3. Europe
      • 6.3.1. Europe depression drug market revenue, by class, 2014 – 2020 (USD Million)
      • 6.3.2. Germany
        • 6.3.2.1. Germany depression drug market revenue, by class, 2014 – 2020 (USD Million)
      • 6.3.3. France
        • 6.3.3.1. France depression drug market revenue, by class, 2014 – 2020 (USD Million)
      • 6.3.4. UK
        • 6.3.4.1. U.K. depression drug market revenue, by class, 2014 – 2020 (USD Million)
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific depression drug market revenue, by class, 2014 – 2020 (USD Million)
      • 6.4.2. China
        • 6.4.2.1. China depression drug market revenue, by class, 2014 – 2020 (USD Million)
      • 6.4.3. Japan
        • 6.4.3.1. Japan depression drug market revenue, by class, 2014 – 2020 (USD Million)
      • 6.4.4. India
        • 6.4.4.1. India depression drug market revenue, by class, 2014 – 2020 (USD Million)
    • 6.5. Latin America
      • 6.5.1. Latin America depression drug market revenue, by class, 2014 – 2020 (USD Million)
      • 6.5.2. Brazil
        • 6.5.2.1. Brazil depression drug market revenue, by class, 2014 – 2020 (USD Million)
    • 6.6. Middle East & Africa
      • 6.6.1. Middle East & Africa depression drug market revenue, by class, 2014 – 2020 (USD Million)
  • Chapter 7. Company Profile
    • 7.1. Forest Laboratories
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product portfolio
      • 7.1.4. Business strategy
      • 7.1.5. Recent developments
    • 7.2. AstraZeneca
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product portfolio
      • 7.2.4. Business strategy
      • 7.2.5. Recent developments
    • 7.3. Eli Lilly and Company
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product portfolio
      • 7.3.4. Business strategy
      • 7.3.5. Recent developments
    • 7.4. H. Lundbeck, Merck & Co.
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product portfolio
      • 7.4.4. Business strategy
      • 7.4.5. Recent developments
    • 7.5. GlaxoSmithKline
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product portfolio
      • 7.5.4. Business strategy
      • 7.5.5. Recent developments
    • 7.6. Naurex
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product portfolio
      • 7.6.4. Business strategy
      • 7.6.5. Recent developments
    • 7.7. Novartis
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product portfolio
      • 7.7.4. Business strategy
      • 7.7.5. Recent developments
    • 7.8. SK Biopharmaceuticals
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product portfolio
      • 7.8.4. Business strategy
      • 7.8.5. Recent developments

Inquiry For Buying

Depression Drug

Please fill out the form. We will contact you within 24 hours:
All fields required...

Request Sample

Depression Drug

Please fill out the form. We will contact you within 24 hours:
All fields required...

List of Contents

Market InsightsReport Scope

×

Avail Free PDF Sample Report

This website is secure and your personal details are safe. Privacy Policy

Thank you for contacting us.

Thank you for your interest in our research report.

We will be sending you the sample copy of the report shortly. Meanwhile, if you have any specific research requirement then please let us know. We will be glad to assist you in case you have any additional questions, so feel free to get in touch

Thank you

Warm regards,
Sales | Manager - International Business and partner Relations
Direct line: +1 347 535 0815
Market Research Store
E-mail: sales@MarketResearchStore.com | Web: www.MarketResearchStore.com